News

Clif Bar launches sixth annual 2 Mile Challenge

BY Michael Johnsen

EMERYVILLE, Calif. — Clif Bar on Wednesday kicked off its sixth annual 2 Mile Challenge, partnering with cyclists to donate $100,000 to bike advocacy nonprofits when riders choose to pedal their bikes instead of drive cars for trips 2 miles or less.

“Joining the 2 Mile Challenge is an easy way to do something good for the environment, while having fun and interacting with the bike community,” stated Ryan Mayo, environmental activism manager at Clif Bar. “As a company that makes food to support people on-the-go, we strive to help sustain the planet for a better future and hope to inspire others to make small changes in their everyday lives to protect the places where people play.”

This year, every bike trip logged by participants in the 2 Mile Challenge is worth $1 for a regional bike advocacy nonprofit, up to a pre-determined monthly dollar cap. Clif Bar will select a new nonprofit each month to benefit from rider miles. All told, the nationwide campaign will donate $100,000 to grassroots bike organizations throughout 2012.

In May, the 2 Mile Challenge donated $6,590 to BikeWalkKC, the unified voice for active living in Kansas City. The Los Angeles County Bike Coalition will benefit from the 2 Mile Challenge in June. Other bike advocacy beneficiaries will be chosen as the year progresses, the company stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Coinstar, Seattle’s Best Coffee bring coffee kiosks to supermarkets, drug stores and mass merchants nationwide

BY Allison Cerra

BELLEVUE, Wash. — Coinstar is bringing its coffee kiosk to various retail channels through an exclusive agreement with Starbucks-owned Seattle’s Best Coffee.

The companies said they initially will roll out 500 Rubi coffee kiosks — which will serve Seattle’s Best Coffee — to grocery, drug and mass merchant retail channels. The Rubi coffee kiosks serving Seattle’s Best Coffee will initially be installed in the Northeast and West Coast regions. As Coinstar expands geographically with its coffee kiosk, it will also pursue additional channels as part of an ongoing rollout.

"We are delighted to introduce the Rubi kiosk, our third automated retail business," Coinstar CEO Paul Davis said. "Just as our Redbox movie rental and Coinstar coin-counting kiosks reimagined retail, we believe our coffee kiosk reimagines the coffee experience for consumers. In addition, we are very pleased to work with Seattle’s Best Coffee, one of the country’s premier coffee brands. Together, we will deliver the kind of quality, convenience and value that we know coffee drinkers on-the-go will appreciate."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Dr. Reddy’s, Merck KGaA partner on biosimilars

BY Alaric DeArment

HYDERABAD, India — A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

Dr. Reddy’s Labs and Merck KGaA subsidiary Merck Serono announced a partnership to develop biosimilar cancer treatments, most of them monoclonal antibodies, for global markets. Based in Darmstadt, Germany, Merck KGaA operates in the United States under the name EMD to distinguish itself from U.S. drug maker Merck.

The companies said the partnership would expand on Dr. Reddy’s presence in the biosimilar space in emerging markets and allow it to participate globally. Currently, a small handful of companies — particularly Teva, Hospira and Novartis generics division Sandoz — dominates the biosimilars market in developed countries, mostly Europe. Part of the healthcare-reform law included a regulatory approval pathway for biosimilars in the United States, but regulations have yet to be finalized.

"We strongly believe that biosimilars is an important area of future growth, and these products give us the opportunity to provide affordable and innovative medicines to patients across the globe," Dr. Reddy’s vice chairman and CEO G.V. Prasad said. "With the recent [European Medicines Agency] and [Food and Drug Administration] guidance on biosimilars, it is clear that any significant player in the field will need strong biologics development, manufacturing and commercialization capabilities. Merck Serono’s and Dr. Reddy’s joint expertise in these fields makes for a powerful global partnership."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES